Ginkgo Bioworks Holdings Statistics
Total Valuation
DNA has a market cap or net worth of $403.96 million. The enterprise value is $417.73 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DNA has 58.21 million shares outstanding. The number of shares has increased by 6.87% in one year.
| Current Share Class | 46.79M |
| Shares Outstanding | 58.21M |
| Shares Change (YoY) | +6.87% |
| Shares Change (QoQ) | +2.60% |
| Owned by Insiders (%) | 16.56% |
| Owned by Institutions (%) | 56.47% |
| Float | 41.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.35 |
| Forward PS | 2.48 |
| PB Ratio | 0.78 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.92, with a Debt / Equity ratio of 0.86.
| Current Ratio | 4.92 |
| Quick Ratio | 4.66 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -51.08% and return on invested capital (ROIC) is -18.06%.
| Return on Equity (ROE) | -51.08% |
| Return on Assets (ROA) | -15.42% |
| Return on Invested Capital (ROIC) | -18.06% |
| Return on Capital Employed (ROCE) | -30.10% |
| Weighted Average Cost of Capital (WACC) | 6.14% |
| Revenue Per Employee | $350,835 |
| Profits Per Employee | -$644,872 |
| Employee Count | 485 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -837,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.27% in the last 52 weeks. The beta is 1.57, so DNA's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | +8.27% |
| 50-Day Moving Average | 7.79 |
| 200-Day Moving Average | 10.27 |
| Relative Strength Index (RSI) | 49.40 |
| Average Volume (20 Days) | 1,192,142 |
Short Selling Information
The latest short interest is 8.00 million, so 13.75% of the outstanding shares have been sold short.
| Short Interest | 8.00M |
| Short Previous Month | 7.26M |
| Short % of Shares Out | 13.75% |
| Short % of Float | 19.21% |
| Short Ratio (days to cover) | 6.61 |
Income Statement
In the last 12 months, DNA had revenue of $170.16 million and -$312.76 million in losses. Loss per share was -$5.64.
| Revenue | 170.16M |
| Gross Profit | 123.18M |
| Operating Income | -308.11M |
| Pretax Income | -313.60M |
| Net Income | -312.76M |
| EBITDA | -267.82M |
| EBIT | -308.11M |
| Loss Per Share | -$5.64 |
Full Income StatementBalance Sheet
The company has $422.62 million in cash and $439.89 million in debt, with a net cash position of -$17.27 million or -$0.30 per share.
| Cash & Cash Equivalents | 422.62M |
| Total Debt | 439.89M |
| Net Cash | -17.27M |
| Net Cash Per Share | -$0.30 |
| Equity (Book Value) | 508.59M |
| Book Value Per Share | 8.74 |
| Working Capital | 375.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$171.06 million and capital expenditures -$7.67 million, giving a free cash flow of -$178.72 million.
| Operating Cash Flow | -171.06M |
| Capital Expenditures | -7.67M |
| Depreciation & Amortization | 40.29M |
| Net Borrowing | -354,000 |
| Free Cash Flow | -178.72M |
| FCF Per Share | -$3.07 |
Full Cash Flow StatementMargins
Gross margin is 72.39%, with operating and profit margins of -181.08% and -183.81%.
| Gross Margin | 72.39% |
| Operating Margin | -181.08% |
| Pretax Margin | -184.30% |
| Profit Margin | -183.81% |
| EBITDA Margin | -157.40% |
| EBIT Margin | -181.08% |
| FCF Margin | n/a |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.87% |
| Shareholder Yield | -6.87% |
| Earnings Yield | -78.10% |
| FCF Yield | -44.63% |
Analyst Forecast
The average price target for DNA is $8.50, which is 22.48% higher than the current price. The consensus rating is "Hold".
| Price Target | $8.50 |
| Price Target Difference | 22.48% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
DNA has an Altman Z-Score of -7.48 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.48 |
| Piotroski F-Score | 1 |
